Merrimack Pharmaceuticals Inc (MACK)

3.02
0.04 1.31
NASDAQ : Health Care
Prev Close 3.06
Open 3.07
Day Low/High 3.02 / 3.08
52 Wk Low/High 5.02 / 11.18
Volume 1.26M
Avg Volume 3.50M
Exchange NASDAQ
Shares Outstanding 130.57M
Market Cap 394.32M
EPS -1.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

These 5 Stocks Under $10 Could Explode Up Soon

These 5 Stocks Under $10 Could Explode Up Soon

Here's a technical look at how to trade several under-$10 stocks triggering breakout trades.

First Week of MACK April 21st Options Trading

First Week of MACK April 21st Options Trading

Investors in Merrimack Pharmaceuticals Inc. saw new options become available this week, for the April 21st expiration.

Immunomedics, Seattle Genetics Lead Biotech Movers on Deal News

Immunomedics, Seattle Genetics Lead Biotech Movers on Deal News

The companies inked a $250 million deal on Friday that could be worth up to $2 billion, thanks to milestone payments.

Here Are the Biotech Stocks Moving Ahead of the Opening Bell

Here Are the Biotech Stocks Moving Ahead of the Opening Bell

McKesson, Bristol-Myers and Varian were having a busy morning.

First Week of September 15th Options Trading For Merrimack Pharmaceuticals (MACK)

First Week of September 15th Options Trading For Merrimack Pharmaceuticals (MACK)

Investors in Merrimack Pharmaceuticals Inc. saw new options begin trading this week, for the September 15th expiration.

Merrimack Names Richard Peters, M.D., Ph.D., As President And CEO

Merrimack Names Richard Peters, M.D., Ph.D., As President And CEO

Industry Veteran Committed to Executing on Vision for the New Merrimack

Closing Bell: Alibaba's Ma Meets With Trump; Nasdaq Hits Record

Closing Bell: Alibaba's Ma Meets With Trump; Nasdaq Hits Record

The Dow Jones Industrial Average's road to 20,000 has another detour as a selloff in crude spooks the energy sector.

Monday's Sights, Sounds and Biotech Buzz From the J.P. Morgan Healthcare Conference

Monday's Sights, Sounds and Biotech Buzz From the J.P. Morgan Healthcare Conference

The $5.2 billion takeout of Ariad Pharma was the biggest news from the closely followed healthcare conference.

Nasdaq Hits Records Even as Crude Selloff Sours Rest of Market

Nasdaq Hits Records Even as Crude Selloff Sours Rest of Market

A selloff in crude oil proves another roadblock in the Dow Jones Industrial Average's pursuit of 20,000.

Dow Steps Back From 20,000 as Crude Selloff Weighs on Energy Sector

Dow Steps Back From 20,000 as Crude Selloff Weighs on Energy Sector

Stocks trade mostly lower Monday with the Dow Jones Industrial Average taking a pause in its race toward 20,000.

Merrimack Sells Pancreatic Cancer Drug to Ipsen for $1 Billion

Merrimack Sells Pancreatic Cancer Drug to Ipsen for $1 Billion

Merrimack Pharmaceuticals agreed to sell oncology treatments, including its pancreatic-cancer treatment Onivyde, to French drugmaker Ipsen.

Biotech Stocks Surge Monday Amid Flurry of Deal Activity

Biotech Stocks Surge Monday Amid Flurry of Deal Activity

Deals, though, weren't the only mover of share prices.

Stock Futures Mostly Lower as Crude Oil Slides Below $53

Stock Futures Mostly Lower as Crude Oil Slides Below $53

Stock futures mostly lower Monday morning amid a slump in crude oil prices.

Merrimack Soars on $1 Billion Sale of Cancer Drugs to Ipsen

Merrimack Soars on $1 Billion Sale of Cancer Drugs to Ipsen

The Nasdaq-listed cancer drug developer is up 43% in premarket trading after promising shareholders special dividends worth more than its closing share price on Friday.

5 Things You Must Know Before the Market Opens Monday

5 Things You Must Know Before the Market Opens Monday

U.S. stock futures are mixed Monday, with futures for the Dow slightly lower; Britain's pound hit its lowest level against the U.S. dollar in more than two months.

Merrimack Concludes Strategic Review; Announces Plan To Divest Assets And Sharpen Strategic Focus

Merrimack Concludes Strategic Review; Announces Plan To Divest Assets And Sharpen Strategic Focus

Company to Sell ONIVYDE® and Generic Version of DOXIL® to Ipsen for Up to $1.025 Billion

Merrimack Pharmaceuticals is Now Oversold (MACK)

Merrimack Pharmaceuticals is Now Oversold (MACK)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Stocks Sport Slight Losses as Dow's Journey to 20,000 Pauses

Stocks Sport Slight Losses as Dow's Journey to 20,000 Pauses

Stocks hold slightly lower on Wednesday as the Dow Jones Industrial Average hovers around 40 points below its 20,000 milestone.

Dow Struggles to Score 20,000 as Nike Earnings Fail to Deliver Big Bump

Dow Struggles to Score 20,000 as Nike Earnings Fail to Deliver Big Bump

The Dow Jones Industrial Average holds agonizingly close to the 20,000 milestone on Wednesday morning after days of flirting with the level.

Merrimack Shares Crash After Halting Breast Cancer Study

Merrimack Shares Crash After Halting Breast Cancer Study

The drug was one of the most important in the company's pipeline, which is undergoing a strategic review.

Dow Futures Creep Higher as Index's 20,000 Milestone Is Within Reach

Dow Futures Creep Higher as Index's 20,000 Milestone Is Within Reach

Stock futures are mixed Wednesday, with the Dow Jones Industrial Average's 20,000 milestone still within reach.

Merrimack Stops The Phase 2 HERMIONE Trial Of MM-302 In HER2-Positive Metastatic Breast Cancer Patients

Merrimack Stops The Phase 2 HERMIONE Trial Of MM-302 In HER2-Positive Metastatic Breast Cancer Patients

Company now plans to provide results of ongoing strategic pipeline review in January

Some 'January Effect' Stock Picks

Some 'January Effect' Stock Picks

Small-caps could also benefit from abating tax-loss selling.

First Week of January 2017 Options Trading For Merrimack Pharmaceuticals (MACK)

First Week of January 2017 Options Trading For Merrimack Pharmaceuticals (MACK)

Investors in Merrimack Pharmaceuticals Inc. saw new options begin trading this week, for the January 2017 expiration.

Merrimack Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish for MACK

Merrimack Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish for MACK

In trading on Thursday, shares of Merrimack Pharmaceuticals Inc. crossed above their 200 day moving average of $6.12, changing hands as high as $6.73 per share.